NCT06641414 - Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). | Biotech Hunter

Enrollment

490

Participants

Timeline

Start Date

January 22, 2025

Primary Completion Date

June 30, 2029

Study Completion Date

December 31, 2029

Conditions

Higher-risk Myelodysplastic Syndrome

Interventions

DRUG

Lisaftoclax (APG-2575)

QD, oral administration.

DRUG

Azacitidine Injection

QD, hypodermic or intravenous injection.

OTHER

Placebo

QD, oral administration.

Trial Locations (2)

NOT_YET_RECRUITING

MD Anderson Cancer Center, Houston

RECRUITING

Peking University People's Hospital, Beijing